Compare STG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STG | XLO |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 49.8M |
| IPO Year | 2017 | 2021 |
| Metric | STG | XLO |
|---|---|---|
| Price | $3.16 | $8.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 4.2K | ★ 32.4K |
| Earning Date | 05-21-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $1.10 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $2.97 | $0.46 |
| 52 Week High | $15.00 | $9.25 |
| Indicator | STG | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 55.05 |
| Support Level | N/A | $0.62 |
| Resistance Level | $3.59 | $8.66 |
| Average True Range (ATR) | 0.21 | 0.49 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 26.39 | 49.38 |
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.